ERBB2 and breast cancer: Bintrafusp alfa is also being tested alone in a separate phase I clinical trial that is recruiting patients with stage II–III HER2-positive breast cancer (NCT03620201) (Table 2) and in a phase II trial for TNBC (NCT04489940) (Table 2).